The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | SpringerLink
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Frontiers | Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Why is Tagrisso not reimbursable as 1st-line treatment in Korea? < Hospital < Article - KBR
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
AstraZeneca's TAGRISSO® (osimertinib) shows potential as a new standard of care in 1st-line EGFR-mutated non-small cell lung cancer at ESMO 2017 Congress
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Scientific Reports
